Page 2 - குறியீட்டு மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from குறியீட்டு மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In குறியீட்டு மருந்துகள் Today - Breaking & Trending Today

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020


InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020
News provided by
Share this article
STOCKHOLM, April 23, 2021 /PRNewswire/  
InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2020. The Annual Report is attached as a PDF and is available on the company s website, https://www.indexpharma.com/en/financial-reports-and-presentations/
.
The printed Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to [email protected], or by mail to InDex Pharmaceuticals Holding AB (publ), Berzelius väg 13, 171 65 Solna, Sweden.
For more information:
Publication
The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on April 23, 2021. ....

Peter Zerhouni , Pr Index Pharmaceuticals Holding , Index Pharmaceuticals Holding , Kindex Pharmaceuticals , Index Pharmaceuticals Holding Ab Annual , Company Certified Adviser , Annual Report , Dex Pharmaceuticals , Immunomodulatory Sequences , Nasdaq First North Growth , குறியீட்டு மருந்துகள் வைத்திருத்தல் , குறியீட்டு மருந்துகள் , ஆண்டு அறிக்கை , டெக்ஸ் மருந்துகள் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி ,

InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe


InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe
STOCKHOLM, April 7, 2021 /PRNewswire/
InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company s DIMS platform has been granted by the European Patent Office.
InDex has a preclinical portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new European patent, entitled
Biologically active oligonucleotides capable of modulating the immune system (patent number 3165607), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the treatment of inflammatory diseases, cancer and infectious diseases. The patent was filed in 2011 and provides an exclusivity period until December 2031, with the possibility of up to 5 years term extension after market approval. ....

Peter Zerhouni , European Patent Office , Prnewswire Index Pharmaceuticals Holding , Kindex Pharmaceuticals , European Patent , Immunomodulatory Sequences , Dex Pharmaceuticals , Nasdaq First North Growth , Dex Pharmagets , ஐரோப்பிய காப்புரிமை அலுவலகம் , குறியீட்டு மருந்துகள் , ஐரோப்பிய காப்புரிமை , டெக்ஸ் மருந்துகள் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி ,